Fjarde AP Fonden Fourth Swedish National Pension Fund Increases Stock Holdings in Illumina, Inc. $ILMN

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Illumina, Inc. (NASDAQ:ILMN) by 16.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,986 shares of the life sciences company’s stock after buying an additional 4,800 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $3,243,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Envestnet Portfolio Solutions Inc. increased its position in shares of Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after buying an additional 99 shares in the last quarter. Moors & Cabot Inc. increased its position in shares of Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock valued at $465,000 after buying an additional 145 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in Illumina by 3.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after purchasing an additional 164 shares in the last quarter. Whipplewood Advisors LLC increased its position in Illumina by 22.2% during the 2nd quarter. Whipplewood Advisors LLC now owns 929 shares of the life sciences company’s stock worth $89,000 after purchasing an additional 169 shares in the last quarter. Finally, Aurora Investment Managers LLC. increased its position in Illumina by 1.3% during the 2nd quarter. Aurora Investment Managers LLC. now owns 15,258 shares of the life sciences company’s stock worth $1,456,000 after purchasing an additional 192 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 4.2%

ILMN opened at $99.01 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The stock has a market capitalization of $15.22 billion, a price-to-earnings ratio of 12.53, a price-to-earnings-growth ratio of 2.34 and a beta of 1.40. The business has a 50-day moving average of $97.97 and a two-hundred day moving average of $92.30. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent research reports. Canaccord Genuity Group lifted their price objective on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Barclays lifted their price objective on Illumina from $90.00 to $95.00 and gave the stock an “underweight” rating in a research report on Thursday, October 2nd. Evercore ISI dropped their price objective on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research report on Tuesday, October 7th. Daiwa Capital Markets cut Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Finally, Citigroup cut Illumina from a “hold” rating to a “strong sell” rating and dropped their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Five investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $115.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.